GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Operating Margin %

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Operating Margin % : -38.17% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Dec. 2023 was HK$-162.8 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the six months ended in Dec. 2023 was HK$426.7 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Dec. 2023 was -38.17%.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % or its related term are showing as below:

HKSE:02315' s Operating Margin % Range Over the Past 10 Years
Min: -149.98   Med: -131.3   Max: -42.69
Current: -42.69


HKSE:02315's Operating Margin % is ranked better than
63.64% of 1023 companies
in the Biotechnology industry
Industry Median: -156.68 vs HKSE:02315: -42.69

Biocytogen Pharmaceuticals (Beijing) Co's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Biocytogen Pharmaceuticals (Beijing) Co's Operating Income for the six months ended in Dec. 2023 was HK$-162.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-334.8 Mil.

Warning Sign:

Biocytogen Pharmaceuticals (Beijing) Co Ltd has never been profitable in the past 3 years. It lost money every year.


Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Operating Margin %
-149.98 -149.08 -113.51 -42.69

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Margin % Get a 7-Day Free Trial -135.08 -126.34 -103.86 -48.09 -38.17

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin %

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % falls into.



Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-334.771 / 784.143
=-42.69 %

Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=-162.849 / 426.657
=-38.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Biocytogen Pharmaceuticals (Beijing) Co Operating Margin % Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Business Description

Traded in Other Exchanges
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC) and other solid tumors.
Executives
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you
Cmb International Investment Management Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Headlines

No Headlines